1)Kenzaka T, Goda K:Serum matrix metalloproteinase 3 in detecting remitting seronegative symmetrical synovitis with pitting edema syndrome;A case report. World J Clin Cases 6:84-87, 2018
2)Olivé A, et al:The clinical spectrum of remitting seronegative symmetrical synovitis with pitting edema;The Catalán Group for the Study of RS3PE. J Rheumatol 24:333-336, 1997
3)Kenzaka T:The relationship between remitting seronegative symmetrical synovitis with pitting edema and vascular endothelial growth factor and matrix metalloproteinase 3. Intern Med 59:1021-1022, 2020
4)Origuchi T, et al:Nine cases of remitting seronegative symmetrical synovitis with pitting edema syndrome complicated with malignancies. Clin Rheumatol 24:206-214, 2012
5)Gorai M, et al:Weighting with the Lansbury articular index improves the correlation of ultrasound score with serum matrix metalloproteinase-3 level in rheumatoid arthritis patients. Mod Rheumatol 24:915-919, 2014
6)Yanai H, et al:Clinical, radiological, and biochemical characteristics in patients with diseases mimicking polymyalgia rheumatica. Clin Interv Aging 4:391-395, 2009
PE syndrome by serologic variables and radiographic methods. Rheumatol Int 30:1677-1680, 2010
8)Origuchi T, et al:High serum matrix metalloproteinase 3 is characteristic of patients with paraneoplastic remitting seronegative symmetrical synovitis with pitting edema syndrome. Mod Rheumatol 22:584-588, 2012